CHAIN at Microbiome Conferences in June

June 1, 2018

CHAIN Chief Executive Dr Edward Green will be speaking at the 2nd Annual Microbiome Discovery and Development Congress. The conference, organised by Oxford Global, will be held in Berlin, June 7-8. This congress brings key leaders and industry experts in the microbiome drug discovery field where the latest strategies and technologies will be discussed.

From the press release:

“The Microbiome industry continues to go from strength to strength, with ever-increasing investment and a number of therapeutics nearing the end of the clinical development period. Though no drugs have yet been approved, the market is undergoing rapid expansion, and it is more important than ever that the challenges raised by this expansion are met.”

Our Head of Partnerships and Licensing, Ben Bradley will speak at the 3rd Annual Microbiome Drug Development Summit in Boston, MA. This conference focuses on development and commercialisation of microbiome-based therapeutics.

Ben’s talk, entitled “Developing Clostridium-Based Microbial Therapeutics for the Treatment of Chronic Gut-Related Diseases” will be in Track A – small molecule discovery and identification.

From the website:

“As microbiome-based therapeutics come in many forms, drug developers battle with critical challenges in product development such as pre-clinical evaluation, clinical trial design, CMC considerations and regulatory uncertainty. With that in mind, the 3rd Annual Microbiome Drug Development Summit will once again unite KOL’s, senior drug developers, microbiome-technology experts and breakthrough researchers to translate the human microbiome into simply effective medicines.”